Skip to main content
. Author manuscript; available in PMC: 2023 Jan 28.
Published in final edited form as: Science. 2022 Jan 27;375(6579):411–418. doi: 10.1126/science.aaz5284

Fig. 4. Quantitative top-down proteomics analysis of PBMC proteoforms from liver transplant recipients.

Fig. 4.

(A) Workflow used to compare patients with transplant excellent (TX); with acute dysfunction, no rejection (ADNR); and with acute rejection (AR). (B) The number of patients whose PBMCs were analyzed in an untargeted fashion. Volcano plot showing differentially expressed proteoforms in (C) AR patients relative to non-AR (TX+ADNR) and (D) TX patients relative to non-TX (ADNR+AR). (E) The number of patients whose PBMCs were analyzed for targeted proteoforms. Volcano plot with the relative levels of the 24 targeted proteoforms in (F) AR versus non-AR and (G) TX versus non-TX. (H) Distributions of the normalized spectral (N.S.) counts of proteins (left) and proteoforms (right) observed in BPA cell types.